The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
incidence and severity of ocular adverse events as identified by eye examination
Timeframe: 1 year
incidence and severity of other adverse events as identified by physical examination, subject reporting, and changes in vital signs
Timeframe: 12 mos